Bausch Health Elects New Board at Annual Meeting

Bausch Health Companies ( (TSE:BHC) ) has provided an update.

On May 13, 2025, Bausch Health Companies held its Annual Meeting of Shareholders where several key proposals were voted on. The shareholders elected a new Board of Directors, approved executive compensation on an advisory basis, sanctioned the 2025 Employee Stock Purchase Plan, and appointed PricewaterhouseCoopers LLP as the independent auditors for the upcoming year. These decisions reflect the company’s ongoing governance and strategic planning efforts, potentially impacting its operational focus and stakeholder relations.

The most recent analyst rating on (TSE:BHC) stock is a Hold with a C$10.00 price target. To see the full list of analyst forecasts on Bausch Health Companies stock, see the TSE:BHC Stock Forecast page.

Spark’s Take on TSE:BHC Stock

According to Spark, TipRanks’ AI Analyst, TSE:BHC is a Neutral.

Bausch Health’s overall score reflects its solid revenue growth and cash flow generation capabilities, countered by high leverage and ongoing profitability issues. Technical indicators and valuation metrics are unfavorable, while recent earnings calls provide some optimism. Addressing financial stability and profitability concerns is crucial for long-term improvement.

To see Spark’s full report on TSE:BHC stock, click here.

More about Bausch Health Companies

Bausch Health Companies Inc. operates in the healthcare industry, focusing on the development, manufacture, and marketing of a range of pharmaceutical, medical device, and over-the-counter products. The company is known for its emphasis on eye health, gastroenterology, and dermatology sectors.

Average Trading Volume: 396,680

Technical Sentiment Signal: Strong Sell

Current Market Cap: C$2.47B

See more insights into BHC stock on TipRanks’ Stock Analysis page.